Paul Sagan - Apr 28, 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role: Director
Signature: /s/ Brian Sandstrom, as Attorney-in-Fact
Stock symbol: MRNA
Transactions as of: Apr 28, 2022
Transactions value $: $0
Form type: 4
Date filed: 5/2/2022, 04:42 PM
Previous filing: Oct 15, 2021
Next filing: Jul 14, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MRNA	Common Stock	Options Exercise	$0	+703		$0.00	703	Apr 28, 2022	Direct	F1
holding	MRNA	Common Stock						15K	Apr 28, 2022	By: Erwin Park LLC	F2
holding	MRNA	Common Stock						76.5K	Apr 28, 2022	By: The Chatham Trust	F2
holding	MRNA	Common Stock						370K	Apr 28, 2022	By: The Paul Sagan Revocable Trust	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MRNA	Restricted Stock Units	Options Exercise	$0	-703	-100%	$0.00^*	0	Apr 28, 2022	Common Stock	703	$0.00	Direct	F1, F3
transaction	MRNA	Stock Option (Right to Buy)	Award	$0	+5.42K		$0.00	5.42K	Apr 28, 2022	Common Stock	5.42K	$142.52	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units convert into common stock on a one-for-one basis.
F2	Erwin Park LLC is an investment vehicle owned by the Reporting Person's children. The Chatham Trust is an irrevocable family trust for which the Reporting Person serves as a trustee. The Paul Sagan Revocable Trust is a revocable trust for which the Reporting Person serves as a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F3	The shares subject to this restricted stock unit award vested in full on April 28, 2022.
F4	This option will become fully vested and exercisable on the earlier of April 28, 2023, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.